Celgene secured the rights to license new therapeutic candidates identified by Forma Therapeutics' screening technique as part of an expanded deal between the firms. The new deal, which could be worth $600 million over the next few years, also gives Celgene the option to purchase Forma. "[T]his second agreement expands across Forma's preclinical and future clinical development efforts, encompassing numerous protein target families and covering a broad range of therapeutic areas," Forma President and CEO Steven Tregay said.

Related Summaries